SYNTHESIS AND CHARACTERIZATION OF SUPRAMOLECULAR BIOVECTOR (SMBV) SPECIFICALLY DESIGNED FOR THE ENTRAPMENT OF IONIC MOLECULES

被引:21
作者
DEMIGUEL, I
IOUALALEN, K
BONNEFOUS, M
PEYROT, M
NGUYEN, F
CERVILLA, M
SOULET, N
DIRSON, R
RIEUMAJOU, V
IMBERTIE, L
SOLERS, C
CAZES, S
FAVRE, G
SAMAIN, D
机构
[1] LAB CIBLAGE THERAPEUT,F-31052 TOULOUSE,FRANCE
[2] CNRS,INST BIOL & GENET CELLULAIRE,F-31062 TOULOUSE,FRANCE
[3] A&S BIOVECTEURS SA,F-31520 TOULOUSE,FRANCE
[4] CTR LUTTE CONTRE CANC CLAUDIUS REGAUD,F-31052 TOULOUSE,FRANCE
来源
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES | 1995年 / 1237卷 / 01期
关键词
NANOPARTICLE; POLYSACCHARIDE; DRUG CARRIER; PHOSPHOLIPID; GENTAMICIN; DOXORUBICIN;
D O I
10.1016/0005-2736(95)00079-I
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Supramolecular biovectors (SMBV) are nanoparticular drug carriers composed of an internal crosslinked solid core externally grafted with fatty acids and surrounded with a phospholipid layer. We show in this paper that the internal core can be derivatized with anionic ligands such as phosphate in order to allow the efficient entrapment of cationic molecules through a process akin to ion exchange. Synthesis of SMBV involved first a cross linking and derivatization step of polysaccharides followed by a homogenization, a drying and a regioselective acylation step. Acylated polysaccharide cores are thus obtained which can be loaded with drugs and wrapped with a phospholipid layer. The SMBVs obtained are characterized through their size, 20 nm, and their ability to filter through 0.22 mu m pore size membrane. Gel permeation chromatography experiments performed with various phospholipid/acylated cores ratios indicate that SMBVs form entities distinct from liposomes and that the optimum phospholipid/acylated cores ratio for this specific type of SMBVs is close to 100%. The supramolecular structure of SMBVs and in particular the spatial proximity between acylated cores and phospholipids is demonstrated through resonance energy transfer experiments. The drug loading capability of SMBVs is illustrated by the preparation of gentamicin and doxorubicin loaded SMBV. The therapeutic potential of SMBVs is then discussed notably in the light of a possible biomimetism with low density lipoproteins (LDL).
引用
收藏
页码:49 / 58
页数:10
相关论文
共 42 条
[1]  
ADORJAR A, 1986, MODERN ANAL ANTIBIOT
[2]  
ASTIER A, 1988, CANCER RES, V48, P1835
[3]   RECEPTOR-MEDIATED ENDOCYTOSIS - INSIGHTS FROM THE LIPOPROTEIN RECEPTOR SYSTEM [J].
BROWN, MS ;
GOLDSTEIN, JL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1979, 76 (07) :3330-3337
[4]   CHRONOPHARMACOKINETICS OF DOXORUBICIN IN PATIENTS WITH BREAST-CANCER [J].
CANAL, P ;
SQALLI, A ;
DEFORNI, M ;
CHEVREAU, C ;
PUJOL, A ;
BUGAT, R ;
ROCHE, H ;
OUSTRIN, J ;
HOUIN, G .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 (03) :287-291
[5]   EFFICIENCY OF CYTOPLASMIC DELIVERY BY PH-SENSITIVE LIPOSOMES TO CELLS IN CULTURE [J].
CHU, CJ ;
DIJKSTRA, J ;
LAI, MZ ;
HONG, K ;
SZOKA, FC .
PHARMACEUTICAL RESEARCH, 1990, 7 (08) :824-834
[6]  
CODDE JP, 1993, ANTICANCER RES, V13, P539
[7]   BINDING OF BIOTINATED-LIPOSOMES TO STREPTAVIDIN IS INFLUENCED BY LIPOSOME COMPOSITION [J].
CORLEY, P ;
LOUGHREY, HC .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1994, 1195 (01) :149-156
[8]  
DAVID SS, 1984, MICROSPHERES DRUG TH
[9]  
DESCHMIDT PC, 1990, CANCER RES, V50, P7476
[10]   INCORPORATION OF PREDNIMUSTINE INTO LOW-DENSITY-LIPOPROTEIN - ACTIVITY AGAINST P388 CELLS IN TISSUE-CULTURE [J].
ELEY, JG ;
HALBERT, GW ;
FLORENCE, AT .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1990, 65 (03) :219-224